对羽扇豆醇在癌症预防方面的潜力的广泛研究强调了它针对各种癌症相关因素的能力。它调节增殖标志物，调节信号通路，包括 PI3K/AKT/mTOR，并影响炎症和凋亡机制。此外，羽扇豆醇表现出选择性杀死癌细胞，同时不伤害正常细胞，从而最大限度地降低对健康组织的毒性作用风险。因此，我们旨在通过回顾各种动物实验，探索羽扇豆醇作为化疗剂和化疗增敏剂的潜在作用。我们对 PubMed、PMC、Cochrane、EuroPMC 和 ctri.gov.in 等数据库进行了全面搜索，以找出相关文章。我们的重点仅放在已发表的研究羽扇豆醇抗癌作用的动物研究上，审稿人独立评估偏倚风险并通过共识解决差异。20 项研究入围。结果表明，羽扇豆醇使肿瘤体积发生变化[Hedges's g：-6.62； 95% CI：-8.68，-4.56； τ2：24.36，I2：96.50%； p < 0.05] 和肿瘤重量 [Hedges g：-3.97； 95% CI：-5.20，-2.49； τ2：2.70，I2：79.27%； p <0.05]。高 I2、负 Egger 值和不对称漏斗图显示了研究之间的发表偏倚。此外，与单独使用羽扇豆醇相比，羽扇豆醇与其他化疗药物联合显示出更好的结果[Hedges g：-6.38； 95% CI：-11.82，-0.94； τ2：46.91； I2：98.68%； p <0.05]。羽扇豆醇还针对各种信号分子和途径发挥抗癌作用。总之，羽扇豆醇可显着减少肿瘤体积和重量。羽扇豆醇与其他化疗药物的结合有望增强抗癌效果。然而，研究之间的高度变异性和发表偏倚的证据表明在解释结果时要谨慎。版权所有 © 2024 Elsevier GmbH。版权所有。

Extensive research on Lupeol's potential in cancer prevention highlights its ability to target various cancer-related factors. It regulates proliferative markers, modulates signaling pathways, including PI3K/AKT/mTOR, and influences inflammatory and apoptotic mechanisms. Additionally, Lupeol demonstrates selectivity in killing cancer cells while sparing normal cells, thus minimizing the risk of toxic effects on healthy tissues.Therefore, we aimed to explore Lupeol's potential roles as a chemotherapeutic agent and as a sensitizer to chemotherapy by reviewing various animal-based studies published on its effects.We conducted a comprehensive search across databases, including PubMed, PMC, Cochrane, EuroPMC, and ctri.gov.in to identify pertinent articles. Our focus was solely on published animal studies examining Lupeol's anti-cancer effects, with reviewers independently assessing bias risk and resolving discrepancies through consensus.20 studies were shortlisted. The results demonstrated that Lupeol brings changes in the tumor volume by [Hedges's g: -6.62; 95 % CI: -8.68, -4.56; τ2: 24.36, I2: 96.50 %; p < 0.05] and tumor weight by [Hedges's g: -3.97; 95 % CI: -5.20, -2.49; τ2: 2.70, I2: 79.27 %; p <0.05]. The high I2, negative Egger's value, and asymmetrical funnel plot show the publication bias among the studies. Further, Lupeol in combination with other chemotherapeutic agents showed better outcomes as compared to them alone [Hedges's g: -6.38; 95 % CI: -11.82, -0.94; τ2: 46.91; I2: 98.68 %; p <0.05]. Lupeol also targets various signaling molecules and pathways to exert an anti-cancer effect.In conclusion, Lupeol significantly reduces tumor volume and weight. Combining Lupeol with other chemotherapy agents shows promise for enhancing anti-cancer effects. However, high variability among studies and evidence of publication bias suggest caution in interpreting results.Copyright © 2024 Elsevier GmbH. All rights reserved.